Tannapfel A, Hahn H A, Katalinic A, Fietkau R J, Kühn R, Wittekind C W
Department of Pathology, Friedrich-Alexander-University of Erlangen-Nürnberg, Germany.
Cancer. 1996 Jan 1;77(1):164-71. doi: 10.1002/(SICI)1097-0142(19960101)77:1<164::AID-CNCR27>3.0.CO;2-2.
The prognosis for patients with renal cell carcinoma depends mainly on pathological stage and grade of the tumor at the time of surgery. Cellular proliferation may prove to be another measure for predicting biologic aggressiveness and, therefore, the prognosis.
The authors compared four different methods to assess proliferation in a series of 87 curatively resected (R0) renal cell carcinomas: flow cytometry analysis (FCM), silver-stained nucleolar organizer regions (AgNOR), and immunohistochemical assessment of the MIB-1 (Ki-67) antigen, and proliferating cell nuclear antigen (PCNA). The results obtained were compared with pathologic stage (according to the International Union Against Cancer [UICC]) and grade with disease-related survival rate; finally, we assessed whether the methods led to similar results.
In each carcinoma examined, we could demonstrate MIB-1, PCNA, and AgNOR dots in varied proportions. Statistical correlations were seen between the tumor grade, the rate of nuclear positivity for MIB-1 and PCNA, and the number of AgNOR dots. Additionally, the MIB-1 index was significantly higher in more advanced tumor stages. A good correlation between MIB-1 and AgNOR as well as for PCNA was found. In univariate survival analysis, tumor stage and grade, MIB-1 and PCNA index, and mean AgNOR number were related significantly to patient survival. On multivariate Cox disease-related survival analysis, stage of disease and MIB-1 were significant independent prognostic factors. Flow cytometry was not related to prognosis nor to other examined parameters.
These results indicated that MIB-1 immunostaining is an additional prognostic parameter for patient outcome. MIB-1 and PCNA immunostaining, as well as AgNOR, demonstrated good correlations among themselves. We failed to establish flow cytometry as a method to predict proliferative capacity or prognosis in renal cell carcinoma patients.
肾细胞癌患者的预后主要取决于手术时肿瘤的病理分期和分级。细胞增殖可能是预测生物学侵袭性及预后的另一指标。
作者比较了四种不同方法来评估87例接受根治性切除(R0)的肾细胞癌的增殖情况:流式细胞术分析(FCM)、银染核仁组织区(AgNOR)以及对MIB-1(Ki-67)抗原和增殖细胞核抗原(PCNA)进行免疫组化评估。将所得结果与病理分期(根据国际抗癌联盟[UICC])、分级及疾病相关生存率进行比较;最后,评估这些方法是否得出相似结果。
在每例所检查的癌组织中,均可发现不同比例的MIB-1、PCNA和AgNOR点。肿瘤分级、MIB-1和PCNA的核阳性率以及AgNOR点数之间存在统计学相关性。此外,在更晚期的肿瘤阶段,MIB-1指数显著更高。发现MIB-1与AgNOR以及PCNA之间存在良好相关性。在单因素生存分析中,肿瘤分期和分级、MIB-1和PCNA指数以及平均AgNOR数与患者生存率显著相关。在多因素Cox疾病相关生存分析中,疾病分期和MIB-1是显著的独立预后因素。流式细胞术与预后及其他所检查参数均无关。
这些结果表明,MIB-1免疫染色是患者预后的一个额外预后参数。MIB-1和PCNA免疫染色以及AgNOR之间相互显示出良好相关性。我们未能将流式细胞术确立为预测肾细胞癌患者增殖能力或预后的方法。